Table 4. Response rate of patients with different MB4 breakpoints treated with bortezomib-based induction therapy.
Breakpoint | ORR | PR | VGPR | CR | SD | PD | ≥VGPR | SD+PD |
---|---|---|---|---|---|---|---|---|
MB4-1 (n=19) | 100% (19/19) | 15.8% (3/19) | 47.4% (9/19) | 36.8% (7/19) | 0 (0/19) | 0 (0/19) | 84.2% (16/19) | 0 (0/19) |
MB4-2/MB4-3 (n=16) | 75% (12/16) | 18.8% (3/16) | 37.5% (6/16) | 18.8% (3/16) | 6.3% (1/16) | 18.8% (3/16) | 56.3% (9/16) | 25% (4/16) |
P value | 0.035 | 1 | 0.734 | 0.285 | 0.457 | 0.086 | 0.132 | 0.035 |